Updated: Oct 20
Medically reviewed by ChinaCureLink Team
Table of Content
Introduction
Patients researching pancreatic cancer or colorectal cancer may encounter autologous dendritic cell (DC) immunotherapy as an emerging cancer-immunotherapy approach. In China, this treatment is available within the Boao Lecheng transformation/application framework under a “pilot first” policy. This guide explains what the treatment is, who may be considered, its estimated cost, and what international patients should know before pursuing it.
Key Takeaways |
|
What Is Autologous DC Therapy?
Autologous dendritic cell therapy uses immune cells collected from the patient's own blood. Mononuclear cells are collected and differentiated into mature dendritic cells in a laboratory. The cells are then loaded with tumor-related antigens and reinfused into the patient.
Dendritic cells are involved in presenting antigens to the immune system. In this approach, the treatment is intended to help the patient's immune system recognize characteristics associated with the tumor. This differs from chemotherapy or radiation therapy, which can directly damage or destroy cancer cells.
The treatment is an immunotherapy approach rather than a stem cell therapy. The clinical value and appropriate role of dendritic-cell immunotherapy for individual cancers should be assessed by qualified oncology specialists.
Is Autologous DC Therapy for Pancreatic Cancer Immunotherapy Available in China?
Yes. Autologous DC therapy for pancreatic cancer immunotherapy in China is available within the Boao Lecheng transformation/application framework under a “pilot first” policy.
This pathway provides a supervised medical-access route for pancreatic cancer immunotherapy in China and should not be interpreted as nationwide regulatory approval for autologous DC therapy throughout China. The treatment is classified as low risk, with registration recorded in 2025.
For patients exploring autologous DC therapy for pancreatic cancer, it is important to distinguish access through the Boao Lecheng pilot framework from broader regulatory approval. Treatment remains subject to individual medical assessment, eligibility requirements, and the applicable requirements of the treating hospital.
See our full guide for China cancer vaccine here.
Where Is the Treatment Offered?
The treatment is offered at Boao Super Hospital.
Technical support is provided by Guangdong Unuo Biotechnology Co., Ltd. The treatment uses autologous dendritic cells, meaning the cells originate from the patient rather than a donor.
Who May Be Eligible?
Potential candidates include patients with pancreatic cancer, colorectal cancer, and other immune-related solid tumors.
Suitability is evaluated based on several clinical factors, including:
Pathological type
Cancer stage
Previous treatments
Overall medical condition
The attending physician conducts a face-to-face assessment, and the final treatment decision is made during consultation. Final eligibility is determined by the treating medical team after a face-to-face consultation and review of the patient's medical records.
How Much Does It Cost?
The estimated cost is ¥388,000 (approximately US$57,700) per session. The USD figure uses an exchange rate of about ¥6.72 per US$1 as a current reference; actual currency conversion may vary.
The stated price is for the treatment session and does not necessarily include consultation, diagnostic testing, hospitalization, translation or coordination services, or travel. Confirm final pricing and the full scope of included services directly with the hospital before making travel arrangements.
Why International Patients May Consider This Option
For some international patients, access to a hospital-based immunotherapy pathway that is not broadly available in their home country may provide another option to discuss with oncology specialists.
The Boao Lecheng pathway gives eligible patients a specific route to explore this autologous DC approach in China. However, the existence of this access pathway does not establish treatment effectiveness for a particular cancer or mean that it is preferable to established cancer treatments. Patients should evaluate the potential benefits, risks, alternatives, evidence, and eligibility with qualified physicians.
How ChinaCureLink Can Help International Patients Access This Treatment
We help international patients explore available treatment options and facilitate communication with appropriate medical specialists. Patients should discuss potential benefits, risks, eligibility, and alternatives directly with qualified physicians. ChinaCureLink does not represent or endorse the treatment technology, manufacturer, or hospital.
Case review: We collect relevant medical history and pancreatic cancer and colorectal cancer-management records to help determine whether a case is appropriate for physician review.
Hospital coordination: We help connect patients with the treating team at Boao Super Hospital in China for an initial assessment.
Online consultation before travel: Patients can discuss potential eligibility, the procedure, and expected next steps with the medical team remotely before committing to international travel.
Coordination support: Depending on the case, this can include translation assistance, appointment scheduling, and logistics coordination.
Considering This Treatment in China?
Before planning travel, speak with a qualified specialist to determine whether the treatment is appropriate for your condition and whether you meet the medical eligibility requirements. ChinaCureLink can help international patients arrange a specialist review and explore the treatment pathway in China. [Request a Medical Review / Speak With a Specialist]
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
Is autologous dendritic cell therapy available in China for pancreatic cancer?
Yes. It is available through the Boao Lecheng transformation/application framework under a “pilot first” policy, at Boao Super Hospital, subject to medical assessment.
How much does autologous DC therapy cost in China?
The estimated cost is ¥388,000, or approximately US$57,700, per session. Patients should confirm the final price and what it includes with the hospital.
Who may qualify for autologous dendritic cell therapy?
Patients with pancreatic cancer, colorectal cancer, and other immune-related solid tumors may be considered. Assessment takes into account pathological type, stage, previous treatments, and overall condition.
Can international patients explore this treatment in China?
Yes, international patients can explore the pathway through medical consultation and eligibility assessment. Final eligibility is determined by the treating medical team.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
